3 studies confirm the value of etanercept therapy in treating juvenile idiopathic arthritis
Friday, June 12, 2009 - 13:28
in Health & Medicine
Three new studies have individually shown the anti-TNF (tumour necrosis factor) therapy etanercept to be effective, with a good safety profile, in children under four years of age with juvenile idiopathic arthritis (JIA), and associated with improved Health-Related Quality of Life (HRQoL) in a substantial proportion of children with JIA.
Read the whole article on Physorg
More from Physorg
Related
- 3 studies confirm the value of etanercept therapy in treating juvenile idiopathic arthritisFri, 12 Jun 2009, 14:31:31 EDT
- Adalimumab therapy effective in AS, RA and PsA patients refractory to other anti-TNF therapiesThu, 12 Jun 2008, 10:36:26 EDT
- Subclinical markers predict relapse in juvenile idiopathic arthritis post methotrexate withdrawalThu, 11 Jun 2009, 11:26:40 EDT
- Gene expression findings a step toward better classification and treatment of juvenile arthritisMon, 29 Jun 2009, 13:08:42 EDT
- Study affirms effectiveness of medication for juvenile rheumatoid arthritisFri, 9 May 2008, 6:28:42 EDT